Jan 25, 2025 · Clinically meaningful and statistically significant results from the Phase 3 BREAKWATER trial show objective response rate of 61% with Pfizer’s BRAFTOVI …

1 day ago · About BRAFTOVI ® (encorafenib) BRAFTOVI is an oral small molecule kinase inhibitor that targets BRAF V600E. Inappropriate activation of proteins in the MAPK signaling …

Dec 20, 2024 · BRAFTOVI is indicated, in combination with cetuximab, for the treatment of adult patients with mCRC with a BRAF V600E mutation, as detected by an FDA-approved test, after …

18 hours ago · NEW YORK, February 03, 2025--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 …

14 hours ago · The Braftovi-Erbitux-chemo combo in December won an FDA accelerated approval based on tumor shrinkage data from the same trial. Now, Pfizer plans to use the …

BRAFTOVI is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by …

Jan 25, 2025 · BRAFTOVI combination regimen is the first and only targeted therapy approved by the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF …

16 hours ago · Pfizer has exclusive rights to BRAFTOVI in the U.S., Canada, Latin America, Middle East, and Africa. Further, Ono Pharmaceutical Co., Ltd. has exclusive rights to …

15 hours ago · Pfizer on Monday released topline data from the Phase III BREAKWATER study, demonstrating that a combination regimen featuring Braftovi significantly improves survival in …

Oct 12, 2023 · BRAFTOVI is FDA-approved, in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as …